Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

Bibliographic Details
Main Authors: Carlos Suso-Ribera, Azucena García-Palacios, Juan P Sanabria-Mazo, Ariadna Colomer-Carbonell, Francesco D'Amico, Michael Maes, Xavier Borràs, Albert Feliu-Soler, Juan V Luciano, Jordi Muchart, Josep Munuera, Halbert Hernández-Negrín, Jarred W Younger, Antoni Rozadilla-Sacanell
Format: Article
Language:English
Published: BMJ Publishing Group 2022-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/1/e055351.full

Similar Items

Similar Items